A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

ClinicalTrials.gov ID: NCT07829406

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07829406. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administrations of NNC0642-1895 in Healthy Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).

Study identification

NCT ID: NCT07829406
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 148 participants

Conditions and interventions

Conditions

Healthy Volunteers

Interventions

NNC0642-1895 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 17, 2026 (Actual)
Primary completion: Sep 12, 2027 (Estimated)
Completion: Sep 12, 2027 (Estimated)
Last update posted: Oct 26, 2026

2026 – 2027

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
ICON-Salt Lake City	Salt Lake City	Utah	84124	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07829406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 26, 2026 · Synced Nov 15, 2026